IP Library Granted Patent US 8,809,001
Granted Patent B2
US 8,809,001 · App. 12/679,753 · Granted Aug 19, 2014

High throughput assays for inhibitors and activators of PAQR receptors

Inventors: Thomas Lyons (Gainesville, FL); Brian R. Kupchak (Gainesville, FL); Jessica L. Smith (Frederick, MD); Ibon Garitaonandia (San Diego, CA)
Assignee: University of Florida Research Foundation, Inc.
G01N33/566G01N2500/10G01N2333/723C07K14/72
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,809,001
App. No.
12/679,753
Granted
Aug 19, 2014
Kind
B2
Abstract

The subject invention provides methods of screening compounds or ligands that interact with human and/or non-human PAQR receptors or fungal osmotin receptors. These methods utilize a colorimetric assay to ascertain whether a compound binds to and activates a PAQR receptor or the osmotin receptor.

Claims (26)

1. A method of identifying candidate ligands of “Progestin and AdipoQ Receptor” (PAQR) receptors, comprising:

a) providing a yeast cell expressing one or more PAQR receptor and a reporter molecule, said reporter molecule driven by a promoter containing a CCCTC binding motif providing a signal in response to activation of said one or more PAQR receptor;

b) contacting said yeast cell with a candidate ligand; and

c) detecting the activation of said one or more PAQR receptor by the development of a signal within the cell or in medium in which the cell is cultured, the detection of a signal indicating the activation of said one or more PAQR receptor.

2. The method according to claim 1 , wherein said one or more PAQR receptor is a human PAQR receptor selected from PAQR1, PAQR2, PAQR3, PAQR4, PAQR5, PAQR6, PAQR7, PAQR8, PAQR9, PAQR10 PAQR11 or various combinations thereof.

3. The method according to claim 2 , wherein said one or more human PAQR receptor or said one or more PAQR receptor is overexpressed in said yeast cell.

4. The method according to claim 1 , wherein said cell is cultured in medium that contains 5%, 4.5%, 4%, 3.5%, 3%, 2.5%, 2%, 1.5%, 1%, 0.5%, 0.25%, 0.10%, 0.05% or 0.025% galactose (w/v).

5. The method according to claim 4 , wherein said cell is cultured in medium that contains galactose at a concentration less than or equal to 0.10% galactose (w/v).

6. The method according to claim 4 , wherein said cell is cultured in medium that contains galactose at a concentration less than or equal to 0.05% galactose (w/v).

7. The method according to claim 1 , wherein said promoter is a truncated FET3 promoter that comprises nucleotides 102 to 603 of SEQ ID NO: 181.

8. The method according to claim 1 , wherein expression of said one or more PAQR receptor is driven by a galactose inducible promoter.

9. The method according to claim 8 , wherein said galactose inducible promoter is GAL1.

10. The method according to claim 1 , wherein said yeast cell is permeabilized prior to detecting the activation of PAQR receptors and β-galactosidase activity is measured.

11. The method according to claim 1 , wherein the activation of said PAQR receptor is detected by contacting intact yeast cells with a ferroxidase substrate and measuring ferroxidase activity.

12. The method according to claim 1 , wherein said reporter molecule is:

a) an enzyme;

b) a fluorescent protein; or

c) a protein providing antibiotic resistance.

13. The method according to claim 12 , wherein said enzyme is an alpha-D-glucosidase, a beta-D-glucosidase, an esterase, a lipase, an acid or alkaline phosphatase, a beta-D-galactosidase, an alpha-L-arabinofuranosidase, a leucine aminopeptidase, a chymotrypsin, an alpha-D-galactosidase, a beta-D-glucuronidase, an aminopeptidase, or a phosphohydralase.

14. The method according to 1 , wherein said promoter is FET3, ZRT1, OLE1, ZRC1 and ZPS1 or truncations thereof containing the CCCTC motif and capable of driving the expression of a gene operably linked thereto.

15. The method according to claim 1 , wherein said candidate ligand is an agonist of said receptor.

16. The method according to claim 1 , wherein the PAQR receptor is PAQR6 and/or PAQR9 and the candidate ligand is a progesterone receptor antagonist or agonist.

17. The method according to claim 2 , wherein said one or more PAQR receptor is human PAQR1, human PAQR2 or a combination thereof.

18. The method according to claim 17 , wherein said one or more PAQR receptor is human PAQR1.

19. The method according to claim 17 , wherein said one or more PAQR receptor is human PAQR2.

20. The method according to claim 2 , wherein said one or more PAQR receptor is a combination of human PAQR1 and human PAQR2.

Assignments (4)
CONFIRMATORY LICENSE Recorded Sep 25, 2014
From: UNIVERSITY OF FLORIDA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 033824/0062 →
CONFIRMATORY LICENSE Recorded Sep 17, 2010
From: UNIVERSITY OF FLORIDA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 025002/0258 →
CONFIRMATORY LICENSE Recorded Sep 17, 2010
From: UNIVERSITY OF FLORIDA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 025002/0318 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2010
From: LYONS, THOMAS JOHN; KUPCHAK, BRIAN R.; SMITH, JESSICA L.; GARITAONANDIA, IBON
To: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
Reel/Frame 024551/0270 →
Continuity (3)
Provisional Application 60974657 · Sep 24, 2007
Provisional Application 61042537 · Apr 4, 2008
Related Publication 20100261178A1 · Oct 14, 2010